Switching to dual therapy (atazanavir/ritonavir+lamivudine) vs. standard triple therapy (atazanavir/ritonavir+2 nucleos[t]ides) is safe and effective in virologically suppressed patients: 48-week results of a randomized clinical trial (SALT study)

dc.contributor.author	Mariño Callejo, Ana Isabel
dc.date.accessioned	2017-06-07T06:58:34Z
dc.date.available	2017-06-07T06:58:34Z
dc.date.issued	2014
dc.identifier.issn	0213-005X
dc.identifier.uri	http://hdl.handle.net/20.500.11940/1231
dc.language.iso	eng
dc.title	Switching to dual therapy (atazanavir/ritonavir+lamivudine) vs. standard triple therapy (atazanavir/ritonavir+2 nucleos[t]ides) is safe and effective in virologically suppressed patients: 48-week results of a randomized clinical trial (SALT study)
dc.type	Publicación de congreso
dc.authorsophos	J. A. Pérez Molina, R. Rubio, A. Rivero, J. Pasquau, I. Suárez, M. Riera, M. Estébanez, J. Santos, J. Sanz, J. Troya, A. Mariño, A. Antela, J. Navarro, H. Esteban,
dc.authorsophos	the GESIDA 7011 Study Group
dc.identifier.sophos	17237
dc.issue.number	Especial
dc.journal.title	Enfermedades Infecciosas y Microbiologia Clinica
dc.organization	Servizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Ferrol::Xerencia da Área de Ferrol::Medicina Interna
dc.rights.accessRights	openAccess
dc.typesophos	Comunicaciones a congresos
dc.volume.number	32

Ficheros en el ítem

Ficheros	Tamaño	Formato	Ver
No hay ficheros asociados a este ítem.